The Causes and Implications of Glass Delamination - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Causes and Implications of Glass Delamination
This article focuses on the history of glass delamination and methods that detect it, both from a compendial and a research perspective.


Pharmaceutical Technology
pp. s6-s9

References

1. FDA, "Advisory to Drug Manufacturers: Formation of Glass Lamellae in Certain Injectable Drugs" (Rockville, MD, Mar. 2011).

2. R.G. Iacocca and M.A. Allgeier, J. Mater. Sci. 42 (3), 801–811 (2007).

3. R.G. Iacocca et al., AAPS PharmSciTech 11 (3), 1340–1349 (2010).

4. R.D. Ennis et al., Pharm. Dev. Technol. 6 (3), 393–405 (2001).

5. V. Dimbleby, J. Pharm. Pharmacol. 5 969–989 (1953).

6. V. Dimbleby, Sci. Sch. Rev. 18 (1937).

7. V. Dimbleby, H.S.Y. Gill, and W.E.S. Turner, J. Soc. Glass Technol. 19, 231–243 (1935).

8. H.S. Blackmore, V. Dimbleby, and W.E.S. Turner, J. Soc. Glass Technol. 122–129 (1923).

9. A. Lavoisier, Mem. Acad. Sci. Inscr. B-Lett. Toulouse, 73–90, (1770).

10. S. Fern, D.S. McPhail, and V. Oakley, Appl. Surf. Sci. 231–232 (6), 510–514 (2004).

11. P. Rogers, D. McPhail, and J. Ryan, Glass Technol. 34 (2), 67–68 (1993).

12. C. Cailleteau et al., Nat. Mater. 7 (10), 978–983 (2008).

13. K.G. Nickel and S. Merke, Key Eng. Mater. 336–338 (4), 1823–1826 (2007).

14. C.M. Jantzen, "Thermodynamic Approach to Glass Corrosion," in Corrosion of Glass, Ceramics, and Ceramic Superconductors: Principles, Testing, Chracterization and Applications, D.E. Clark and B.K. Zoitis, Eds. (Noyes Publications, Park Ridge, NJ, 1992), pp. 153–217.

15. W.B. White, "Theory of Corrosion of Glass and Ceramics," in Corrosion of Glass, Ceramics, and Ceramic Superconductors: Principles, Testing, Chracterization and Applications, D.E. Clark and B.K. Zoitis, Eds. (Noyes Publications, Park Ridge, NJ, 1992), pp. 2–28.

16. L. Liu et al., Invest. Ophthalmol. Vis. Sci. 52 (2), 1023–1034 (2011).

17. J.S. Bee et al., Biotechnol. Bioeng. 105 (1), 121–129 (2010).

18. J.S. Bee et al., J. Pharm. Sci. 98 (9), 3218–3238 (2009).

19. M. Hoehne et al., J. Pharm. Sci. 100 (1), 123–132 (2011).

20. A. Rosenberg, AAPS J. 8 (3), E501–E507 (2006).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here